TP53 and B-cell chronic lymphocytic leukemia: While the GLOW study which compared the efficacy of IbVen to ChlO excluded CLL with known TP53 aberrancy, five of seven unfit/older patients with CLL exhibiting centrally-tested TP53 aberrancy treated with IbVen remained MRD negative at month 18 following completion of treatment [34].